



Berhyanda Limited
Globe House, Ground & First Floors
23 Kennedy Avenue
1075 Nicosia – Cyprus
Tel: +357 22007960

7 April 2026

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400001

Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India
Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011 (“SEBI Takeover Regulations”)

Pursuant to Regulation 31(4) of the SEBI Takeover Regulations, we, Berhyanda Limited, promoter of Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited), along with following persons acting in concert with Berhyanda Limited i.e., Jasmiral Holdings Limited (Promoter), Berhyanda Midco Limited and Jasmiral Midco Limited, hereby declare that we have not made any encumbrance on the shares of Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited), directly or indirectly, other than those already disclosed during the financial year 2025-26.

This is for your information and record.

Thanking you,
Yours faithfully,
For Berhyanda Limited

A handwritten signature in black ink, appearing to read 'CP', is written over a horizontal line.

Christodoulos Patsalides
Director

Copy to:
The Audit Committee of Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited)